OmniPathology Announces the Launch of its Oropharyngeal HPV PCR Test

OmniPathology

New Human Papillomavirus (HPV) Oropharyngeal PCR Test Helps Screen for Oropharyngeal Cancer and Detect Early Precancerous Lesions

PASADENA, Calif., July 12 10, 2022 (GLOBE NEWSWIRE) — OmniPathology, an independent, physician-owned and operated pathology laboratory, today announced the launch of a new oral test for human papillomavirus (HPV), which can cause cancer. The oral HPV test is a laboratory developed test (LDT) performed on a Roche cobas® 6800 and 8800 broadband platforms.

The oral HPV test detects 14 high-risk HPV strains. It is performed via a throat swab submitted to OmniPathology, a CLIA-certified lab in Pasadena, for testing. Patients who test positive are advised to undergo a thorough examination by an ENT doctor and may require close follow-up. Detecting and removing precancerous oral and oropharyngeal lesions early can help significantly reduce the risk of progression to cancer. This test will be offered to primary care physicians and gynecologists, LGBTQIA+ clinics, dentists, oral surgeons and ENT practices across the country as part of routine patient examinations.

“The launch of this oropharyngeal HPV test is an exciting step for OmniPathology, especially since this is an underserved area for diagnostic testing. As a science-led and service-driven organization, OmniPathology continues to deliver cutting-edge molecular testing that can impact patient care and improve the quality of service our physician customers provide to their patients.” , said Mohammad Kamal MD, Founder and CEO of OmniPathology. “We continue to expand our testing menu to target sexually transmitted infections and other viral illnesses.”

Oral HPV has no symptoms and is transmitted through skin-to-skin contact. Risk factors for oral HPV include oral sex, having multiple partners, smoking, drinking alcohol, sharing drinks and utensils, and a weakened immune system. Oral HPV is often found in patients with genital HPV and is common in sexually active people and their contacts.

HPV is the most common STI in the United States and the rate of infection has steadily increased over the past 30 years. HPV infections can cause 70% of oral cancers, and according to the Centers for Disease Control (CDC), 10% of men and 3.6% of women have oral HPV.

For more information on the new oral HPV test, please contact OmniPathology at http://omnipathology.com/closer-look.

About OmniPathology:
OmniPathology is a highly complex, CLIA-certified, physician-owned pathology laboratory in Pasadena, CA. It specializes in gastrointestinal pathology, gynecology and men’s health and provides state-of-the-art molecular and cytogenetic testing to complement its pathology and immunohistochemistry testing with a particular focus on screening and early detection of prostate cancers. anus, cervix, colon and esophagus. . OmniPathology’s infectious menu includes HPV, other STIs, and gynecological and gastrointestinal infectious panels.

Contact:

Tom Woolf
Director, Public Relations
Publicity Gumas
[email protected], 415.621.7575

Comments are closed.